The U.S. Court of Appeals for the Federal Circuit (CAFC) on Tuesday in a precedential decision authored by Judge Taranto affirmed a New Jersey district court’s ruling that Teva Pharmaceuticals USA did not prove the asserted claims of Janssen Pharmaceuticals’ patent for dosing regimens of antipsychotic medications invalid for obviousness.
Recent Posts
- CAFC Upholds Win for Janssen on Patent for Antipsychotic Med Dosing Regimen
- IP Innovators – From Patent Office to Managing Partner: Chris Agrawal’s Journey
- In Sonos v. Google, the Federal Circuit Has a Chance to Fix Its Prosecution Laches Doctrine
- Perspectives on the PTAB’s 70% All Claims Invalidation Rate
- Moratorium on State AI Regulation Scrapped in Senate Version of Trump’s ‘Big Beautiful Bill’